Clinical Trials Logo

Heart Catheterization clinical trials

View clinical trials related to Heart Catheterization.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03142126 Completed - Clinical trials for Coronary Angiography

Accelerated Ambulation After Vascular Access Closure Device

Start date: August 6, 2014
Phase: N/A
Study type: Interventional

The researchers are seeking to study whether or not there is benefit in keeping patients flat after Angioseal for extended periods of time after diagnostic heart catheterization or if a more aggressive approach of early ambulation would be just as safe while improving cost and patient comfort.

NCT ID: NCT00968032 Completed - Clinical trials for Foramen Ovale, Patent

Procedural Success and Safety of the Nit-Occlud® Patent Foramen Ovale (PFO) Closure Device and Its Application System

09k003
Start date: July 2009
Phase: N/A
Study type: Interventional

The foramen ovale is an opening in the interatrial septum. It results from an incomplete coverage of the ostium secundum. In 10 to 24% of the general population incomplete fibrosis of the interatrial septum is a clinical finding and is defined as a patent foramen ovale (PFO). The Nit-Occlud® PFO umbrella is a permanent implant for closing PFOs that is implanted in the PFO using minimally invasive catheter technology. The umbrella is made from Nitinol, a material with superelastic properties, which, in its relaxed state, has the form of a double umbrella. This is a single-center, non-comparative, prospective interventional clinical investigation involving 1 center in Germany to assess the effectiveness, safety and practicability of implantation of the Nit-Occlud PFO® Closure Device.

NCT ID: NCT00818753 Completed - Clinical trials for Heart Catheterization

Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention

Start date: January 2009
Phase: Phase 2
Study type: Interventional

To assess whether two doses of dabigatran etexilate (110 mg twice daily (b.i.d) and 150 mg twice daily (b.i.d)) as compared to unfractionated heparin (UFH), both in addition to a standard dual antiplatelet regimen, provide sufficient anticoagulation in the setting of elective percutaneous coronary intervention (PCI).